A citation-based method for searching scientific literature

Jinyu Yu, Jiayi Yu, Xiaowen Wu, Qian Guo, Ting Yin, Zhiyuan Cheng, Jie Dai, Yan Kong, Jun Guo. Clin Sci (Lond) 2020
Times Cited: 3







List of co-cited articles
46 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.
Helena Cirenajwis, Martin Lauss, Henrik Ekedahl, Therese Törngren, Anders Kvist, Lao H Saal, Håkan Olsson, Johan Staaf, Ana Carneiro, Christian Ingvar,[...]. Mol Oncol 2017
44
100

Whole-genome landscapes of major melanoma subtypes.
Nicholas K Hayward, James S Wilmott, Nicola Waddell, Peter A Johansson, Matthew A Field, Katia Nones, Ann-Marie Patch, Hojabr Kakavand, Ludmil B Alexandrov, Hazel Burke,[...]. Nature 2017
503
100

KIT as a therapeutic target in metastatic melanoma.
Richard D Carvajal, Cristina R Antonescu, Jedd D Wolchok, Paul B Chapman, Ruth-Ann Roman, Jerrold Teitcher, Katherine S Panageas, Klaus J Busam, Bartosz Chmielowski, Jose Lutzky,[...]. JAMA 2011
520
66

Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
H S Kim, M Jung, H N Kang, H Kim, C-W Park, S-M Kim, S J Shin, S H Kim, S G Kim, E K Kim,[...]. Oncogene 2017
44
66

Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.
Xiaodong Feng, Maria Sol Degese, Ramiro Iglesias-Bartolome, Jose P Vaque, Alfredo A Molinolo, Murilo Rodrigues, M Raza Zaidi, Bruce R Ksander, Glenn Merlino, Akrit Sodhi,[...]. Cancer Cell 2014
302
66

Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities.
Roy Rabbie, Peter Ferguson, Christian Molina-Aguilar, David J Adams, Carla D Robles-Espinoza. J Pathol 2019
51
66

Kinase gene fusions in defined subsets of melanoma.
Jacqueline Turner, Kasey Couts, Jamie Sheren, Siriwimon Saichaemchan, Witthawat Ariyawutyakorn, Izabela Avolio, Ethan Cabral, Magdelena Glogowska, Carol Amato, Steven Robinson,[...]. Pigment Cell Melanoma Res 2017
26
66

The NF1 gene in tumor syndromes and melanoma.
Maija Kiuru, Klaus J Busam. Lab Invest 2017
65
66

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
Kevin Kalinsky, Sandra Lee, Krista M Rubin, Donald P Lawrence, Anthony J Iafrarte, Darell R Borger, Kim A Margolin, Mario M Leitao, Ahmad A Tarhini, Henry B Koon,[...]. Cancer 2017
50
66

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
John M Kirkwood, Lars Bastholt, Caroline Robert, Jeff Sosman, James Larkin, Peter Hersey, Mark Middleton, Mireille Cantarini, Victoria Zazulina, Karin Kemsley,[...]. Clin Cancer Res 2012
205
66

Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).
Su Jin Lee, Tae Min Kim, Yu Jung Kim, Kee-Taek Jang, Hyo Jin Lee, Soon Nam Lee, Mi Sun Ahn, In Gyu Hwang, Suee Lee, Moon-Hee Lee,[...]. Oncologist 2015
27
66

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
66

Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas.
Hai-Tao Niu, Qi-Ming Zhou, Fang Wang, Qiong Shao, Yuan-Xiang Guan, Xi-Zhi Wen, Li-Zhen Chen, Qi-Sheng Feng, Wei Li, Yi-Xin Zeng,[...]. Pigment Cell Melanoma Res 2013
33
66

TERT copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma.
Sifan Yu, Tianxiao Xu, Jie Dai, Meng Ma, Huan Tang, Zhihong Chi, Lu Si, Chuanliang Cui, Xinan Sheng, Yan Kong,[...]. Onco Targets Ther 2018
11
66

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Evgeny Levchenko, Vanna Chiarion Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko,[...]. N Engl J Med 2019
312
66

Sunitinib therapy for melanoma patients with KIT mutations.
David R Minor, Mohammed Kashani-Sabet, Maria Garrido, Steven J O'Day, Omid Hamid, Boris C Bastian. Clin Cancer Res 2012
136
66

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
F Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, Jonathan A Fletcher, Meijun Zhu, Adrian Marino-Enriquez, Philip Friedlander, Rene Gonzalez, Jeffrey S Weber, Thomas F Gajewski,[...]. J Clin Oncol 2013
315
66

Targeting the ERK Signaling Pathway in Melanoma.
Paola Savoia, Paolo Fava, Filippo Casoni, Ottavio Cremona. Int J Mol Sci 2019
50
66

Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features.
Ki Rang Moon, Yoo Duk Choi, Jung Min Kim, Suna Jin, Min-Ho Shin, Hyun-Jeong Shim, Jee-Bum Lee, Sook Jung Yun. J Invest Dermatol 2018
30
66

Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma.
J William Harbour, Elisha D O Roberson, Hima Anbunathan, Michael D Onken, Lori A Worley, Anne M Bowcock. Nat Genet 2013
287
66

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Jacob Schachter, Antoni Ribas, Georgina V Long, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. Lancet 2017
560
66

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
Alain P Algazi, Rosaura Esteve-Puig, Adi Nosrati, Brian Hinds, Adele Hobbs-Muthukumar, Prachi Nandoskar, Susana Ortiz-Urda, Paul B Chapman, Adil Daud. Pigment Cell Melanoma Res 2018
21
66

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
Richard D Carvajal, Donald P Lawrence, Jeffrey S Weber, Thomas F Gajewski, Rene Gonzalez, Jose Lutzky, Steven J O'Day, Omid Hamid, Jedd D Wolchok, Paul B Chapman,[...]. Clin Cancer Res 2015
63
66

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
Reinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, Ana Arance, Caroline Dutriaux, Anna Maria Di Giacomo, Piotr Rutkowski, Michele Del Vecchio, Ralf Gutzmer, Mario Mandala,[...]. Lancet Oncol 2017
183
66

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.
Bradley Garman, Ioannis N Anastopoulos, Clemens Krepler, Patricia Brafford, Katrin Sproesser, Yuchao Jiang, Bradley Wubbenhorst, Ravi Amaravadi, Joseph Bennett, Marilda Beqiri,[...]. Cell Rep 2017
42
66

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.
Felicity Newell, Yan Kong, James S Wilmott, Peter A Johansson, Peter M Ferguson, Chuanliang Cui, Zhongwu Li, Stephen H Kazakoff, Hazel Burke, Tristan J Dodds,[...]. Nat Commun 2019
68
66

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
Bianca Devitt, Wendy Liu, Renato Salemi, Rory Wolfe, John Kelly, Chin-Yuan Tzen, Alexander Dobrovic, Grant McArthur. Pigment Cell Melanoma Res 2011
160
66

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
J Guo, R D Carvajal, R Dummer, A Hauschild, A Daud, B C Bastian, S N Markovic, P Queirolo, A Arance, C Berking,[...]. Ann Oncol 2017
58
66

Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3.
Marcel Martin, Lars Maßhöfer, Petra Temming, Sven Rahmann, Claudia Metz, Norbert Bornfeld, Johannes van de Nes, Ludger Klein-Hitpass, Alan G Hinnebusch, Bernhard Horsthemke,[...]. Nat Genet 2013
268
66

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Jun Guo, Lu Si, Yan Kong, Keith T Flaherty, Xiaowei Xu, Yanyan Zhu, Christopher L Corless, Li Li, Haifu Li, Xinan Sheng,[...]. J Clin Oncol 2011
417
66

The mutational landscape of mucosal melanoma.
Kelsey W Nassar, Aik Choon Tan. Semin Cancer Biol 2020
25
66

STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.
Julie Delyon, Sylvie Chevret, Thomas Jouary, Sophie Dalac, Stephane Dalle, Bernard Guillot, Jean-Philippe Arnault, Marie-Françoise Avril, Christophe Bedane, Guido Bens,[...]. J Invest Dermatol 2018
18
66

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Paolo A Ascierto, Dirk Schadendorf, Carola Berking, Sanjiv S Agarwala, Carla Ml van Herpen, Paola Queirolo, Christian U Blank, Axel Hauschild, J Thaddeus Beck, Annie St-Pierre,[...]. Lancet Oncol 2013
459
66

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean Jacques Grob,[...]. N Engl J Med 2014
66

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Jeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, Vernon K Sondak, Georgina V Long, Merrick I Ross, Alexander J Lazar, Mark B Faries, John M Kirkwood, Grant A McArthur,[...]. CA Cancer J Clin 2017
794
66

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Michael Krauthammer, Yong Kong, Byung Hak Ha, Perry Evans, Antonella Bacchiocchi, James P McCusker, Elaine Cheng, Matthew J Davis, Gerald Goh, Murim Choi,[...]. Nat Genet 2012
763
66

Epigenetics of malignant melanoma.
Bruce Moran, Romina Silva, Antoinette S Perry, William M Gallagher. Semin Cancer Biol 2018
32
66

PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
Xiaowen Wu, Jiayi Yu, Junya Yan, Jie Dai, Lu Si, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Meng Ma, Huan Tang,[...]. Cancer Biol Ther 2018
10
66

Mutational status of naevus-associated melanomas.
D Shitara, G Tell-Martí, C Badenas, M M S S Enokihara, L Alós, A B Larque, N Michalany, J A Puig-Butille, C Carrera, J Malvehy,[...]. Br J Dermatol 2015
22
66

Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
Rui Wang, Yupeng He, Valerie Robinson, Ziping Yang, Paul Hessler, Loren M Lasko, Xin Lu, Anahita Bhathena, Albert Lai, Tamar Uziel,[...]. Mol Cancer Ther 2018
19
66

A landscape of driver mutations in melanoma.
Eran Hodis, Ian R Watson, Gregory V Kryukov, Stefan T Arold, Marcin Imielinski, Jean-Philippe Theurillat, Elizabeth Nickerson, Daniel Auclair, Liren Li, Chelsea Place,[...]. Cell 2012
66

Melanoma.
Dirk Schadendorf, Alexander C J van Akkooi, Carola Berking, Klaus G Griewank, Ralf Gutzmer, Axel Hauschild, Andreas Stang, Alexander Roesch, Selma Ugurel. Lancet 2018
314
66

Distinct sets of genetic alterations in melanoma.
John A Curtin, Jane Fridlyand, Toshiro Kageshita, Hetal N Patel, Klaus J Busam, Heinz Kutzner, Kwang-Hyun Cho, Setsuya Aiba, Eva-Bettina Bröcker, Philip E LeBoit,[...]. N Engl J Med 2005
66

Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma.
Winnie S Liang, William Hendricks, Jeffrey Kiefer, Jessica Schmidt, Shobana Sekar, John Carpten, David W Craig, Jonathan Adkins, Lori Cuyugan, Zarko Manojlovic,[...]. Genome Res 2017
61
66

The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
Karen E Sheppard, Grant A McArthur. Clin Cancer Res 2013
152
66

Malignant melanoma of the mucous membranes: a review of 119 cases.
P DeMatos, D S Tyler, H F Seigler. Ann Surg Oncol 1998
52
33

Germline BAP1 alterations in familial uveal melanoma.
Karan Rai, Robert Pilarski, Getachew Boru, Muneeb Rehman, Ahmad H Saqr, James B Massengill, Arun Singh, Meghan J Marino, Frederick H Davidorf, Colleen M Cebulla,[...]. Genes Chromosomes Cancer 2017
35
33

Primary diffuse meningeal melanomatosis - a rare form of meningeal melanoma: case report.
Tomasz Garbacz, Michał Osuchowski, Halina Bartosik-Psujek. BMC Neurol 2019
4
33

"White" nevi and "red" melanomas: association with the RHC phenotype of the MC1R gene.
Iris Zalaudek, Wayne Meiklejohn, Giuseppe Argenziano, Amy E Thurber, Richard A Sturm. J Invest Dermatol 2009
19
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.